Written Question·Department of Health and Social Care·UIN HL1764
Breast Cancer: Drugs
Tabled: 7 July 2026
Answered: 16 July 2026
Question
To ask His Majesty's Government what assessment they have made of the impact of the decision not to approve the use of Enhertu on the NHS for patients in England affected by HER2-low metastatic breast cancer.
Answer
HER2‑low breast cancer is managed with treatments for HER2‑negative breast cancer. The National Institute for Health and Care Excellence (NICE) has published guidance recommending a number of medicines for the treatment of HER2-negative breast cancer whic...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN HL1764) →